UN High-Level Meeting on TB, 2018

UN High-Level Meeting on TB, 2018
Name	UN High-Level Meeting on TB, 2018
Date	26 September 2018
Venue	United Nations Headquarters, New York City
Organizers	United Nations General Assembly; World Health Organization; Stop TB Partnership
Participants	Member States of the United Nations, heads of state and government, World Bank, Gavi, the Vaccine Alliance, Bill & Melinda Gates Foundation
Result	Political Declaration on the Fight Against Tuberculosis

UN High-Level Meeting on TB, 2018

The 2018 UN High-Level Meeting on Tuberculosis convened heads of state and government at United Nations General Assembly to address the World Health Organization estimates of global tuberculosis burden. The meeting produced a Political Declaration aimed at accelerating commitments by Member States of the United Nations and international institutions such as the World Bank and Global Fund to Fight AIDS, Tuberculosis and Malaria to scale up diagnosis, treatment and prevention. Delegations from low‑, middle‑ and high‑income countries, together with representatives from Gavi, the Vaccine Alliance and philanthropic organizations like the Bill & Melinda Gates Foundation, attended to mobilize resources and accountability mechanisms.

Background and context

The summit was convened against a backdrop of continuing high global incidence and mortality cited by the World Health Organization Global Tuberculosis Report and framed by the Sustainable Development Goals target 3.3. Prior UN health high-level meetings on HIV/AIDS in 2001 and Non-communicable diseases in 2011 provided diplomatic precedents for disease‑specific political commitments. The Stop TB Partnership and civil society coalitions such as Results UK and Treatment Action Group campaigned for a head‑of‑state level meeting following repeated calls from affected country coalitions including delegations from India, South Africa, Indonesia, and Philippines. Scientific urgency drew on research from institutions including University of Cape Town, Imperial College London, and Johns Hopkins University emphasizing multidrug‑resistant tuberculosis and gaps in paediatric treatment.

Summit organization and participants

The meeting was scheduled by the President of the United Nations General Assembly and co‑hosted by the United Nations, with logistical support from the World Health Organization and advocacy leadership from the Stop TB Partnership. Heads of state such as leaders from United Kingdom, United States, India, and Russia sent envoys or attended, alongside ministers from China, Brazil, South Africa, and Nigeria. International financial institutions, including the World Bank and International Monetary Fund, participated in side events, as did multilateral health initiatives like the Global Fund to Fight AIDS, Tuberculosis and Malaria and Gavi, the Vaccine Alliance. Civil society representatives from Médecins Sans Frontières, Amnesty International, and regional networks including African Union delegations and ASEAN representatives held parallel forums. Scientific contributors included experts affiliated with Harvard University, Karolinska Institutet, and the European Centre for Disease Prevention and Control.

Declaration and commitments

The Political Declaration on the Fight Against Tuberculosis called for intensified domestic financing by Member States of the United Nations, expanded support from the Global Fund to Fight AIDS, Tuberculosis and Malaria, and increased research investment from funders such as the Bill & Melinda Gates Foundation and national agencies including National Institutes of Health and European Commission. It specified targets aligned with the End TB Strategy adopted by the World Health Assembly, urging scale‑up of universal health coverage initiatives championed by organizations like World Health Organization and World Bank. The declaration urged enhanced action on multidrug‑resistant tuberculosis, referencing diagnostic tools developed at institutions such as FIND (Foundation for Innovative New Diagnostics) and treatment regimens informed by research from Centers for Disease Control and Prevention. Commitments included pledges to improve surveillance systems supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and to integrate TB prevention into national plans similar to initiatives by UNAIDS.

Global and national follow-up actions

Following the meeting, the World Health Organization and the Stop TB Partnership coordinated mechanisms for monitoring implementation, including reporting to the United Nations General Assembly and engagement with the Global Fund to Fight AIDS, Tuberculosis and Malaria replenishment processes. Several countries, including India, South Africa, Philippines, and Indonesia, announced national action plans and increased budgets modeled on health financing proposals from the World Bank and technical assistance from WHO Regional Office for South‑East Asia. Research funders such as the Wellcome Trust and Bill & Melinda Gates Foundation launched calls for proposals addressing drug‑resistant TB and vaccine development, coordinating with academic centers like London School of Hygiene & Tropical Medicine and Pasteur Institute.

Outcomes and impact

The meeting elevated TB on the diplomatic agenda, prompting renewed funding rounds at the Global Fund to Fight AIDS, Tuberculosis and Malaria and influencing national budget allocations in high‑burden countries like India and South Africa. Advocacy groups such as Treatment Action Group reported increased political visibility, while scientific collaborations between institutions including Imperial College London and University of Cape Town accelerated trial enrollments for novel therapeutics. However, independent monitoring by civil society coalitions and agencies like World Health Organization tracked mixed progress against the declaration’s targets, noting uneven implementation and persistent gaps in access to paediatric formulations and diagnostics.

Criticism and controversies

Critics including Médecins Sans Frontières and Amnesty International argued the Political Declaration lacked binding financing mechanisms and measurable timelines, contrasting it with binding treaties such as the Framework Convention on Tobacco Control. Observers pointed to insufficient new funding commitments from some high‑income states such as United States and questioned the role of private funders like the Bill & Melinda Gates Foundation in shaping priorities. Civil society highlighted ongoing challenges in addressing multidrug‑resistant tuberculosis and equitable access to novel drugs, citing slow uptake despite endorsements by the World Health Organization. Disputes arose over accountability processes and the adequacy of follow‑up reporting to the United Nations General Assembly.

Category:United Nations health conferences